Core Competence
-
Regulatory Affairs
Experienced in filing application, exntension upon expiration, or other regulatory changes of marketing authorizations.
-
Market Access
Negotiate with Bureau of National Health Insurance (BNHI) to receive adequate reimbursement prices on all targeted indications.
-
Medical Affairs
Familiarize HCP's with soon-to-launch or new-to-market products and their positions in treatment plans, provide market access with supporting documents, arrange post-marketing studies, and train internal sales representatives on product knowledge.
-
Marketing
Budget and execute advertising and promotion events including detailing meals, seminars, and congresses, aiming to maximize the share of voice, in addition to planning and tracking listing plan and sales achievement progress.
-
Sales
Visit HCP's to detailly explain product knowledge and benefits to patients, in order to facilitate listing in hospitals followed by growth in prescriptions.
-
Compliance
All employees need to comply with the "Code of Conduct", and all sales and marketing expenses will be re-checked for complaince, with certain expenses even requiring pre-approval.
-
IT
Fully functional software and digital signature systems not only facilitate the implementation of internal control/audit and increase efficiency of internal process, but also further maximize sales efficiency by providing effective data analysis.
-
Warehousing & Logistics
Warehousing & Logistic services are contracted to internationally recognized partners with strict adherence to GDP, and they are periodically audited by our QA personnel on inventory and quality compliance.
-
Quality Assurance & Pharmacovigilance
To ensure patient safety, our QA team promptly reports issues of non-conforming products or adverse effects and takes suitable actions accordingly upon demand.
Product Life-Cycle Management
Based on the requests of individual innovator, EB Pharma can begin tailor-made services from any stage of the product-life-cycle.
-
Pre-Entry
Our RA team collaborates with innovators to provide documents needed for MA approval, folowed by market access team applying for BNHI prices by balancing indications and prices. In the mean time, MSL's pay frequent visits to HCP's to pre-establish share of voice.
-
Growth
Substantial sales and marketing budget is allocated in the early stage of market entry. In addition to diligently making detailing calls to HCP's, seminars, detailing meals, and congress participations are planned extensively to faciliate listing and increase in prescription.
-
Mature-Decline
When growth becomes saturated, revenue may decline due to decreasing BNHI prices, competiton from generics or other innovator products with the same indication. Significant field visits and events for reminding purpose would be necessary to maintain share of voice.
-
Divestment or De-Listing
When operating loss occurs due to low BNHI prices, EB may offer to purchase the franchise altogehter to allow patients continued access to innovator products. If the innovator decides to withdraw instead, EB would communicate with concerned HCP's to gradually de-list the products from Taiwan market after substitutive drugs can be arranged.
-
Pre-Entry
Our RA team collaborates with innovators to provide documents needed for MA approval, folowed by market access team applying for BNHI prices by balancing indications and prices. In the mean time, MSL's pay frequent visits to HCP's to pre-establish share of voice.
-
Growth
Substantial sales and marketing budget is allocated in the early stage of market entry. In addition to diligently making detailing calls to HCP's, seminars, detailing meals, and congress participations are planned extensively to faciliate listing and increase in prescription.
-
Mature-Decline
When growth becomes saturated, revenue may decline due to decreasing BNHI prices, competiton from generics or other innovator products with the same indication. Significant field visits and events for reminding purpose would be necessary to maintain share of voice.
-
Divestment or De-Listing
When operating loss occurs due to low BNHI prices, EB may offer to purchase the franchise altogehter to allow patients continued access to innovator products. If the innovator decides to withdraw instead, EB would communicate with concerned HCP's to gradually de-list the products from Taiwan market after substitutive drugs can be arranged.